Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients.
COVID-19
Convalescent plasma therapy
Mortality
Passive immunization
SARS Cov-2
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
03
01
2022
revised:
03
05
2022
accepted:
06
05
2022
pubmed:
27
5
2022
medline:
6
12
2022
entrez:
26
5
2022
Statut:
ppublish
Résumé
The role of plasma therapy in the management of the COVID-19, pandemic has been speculated. However, in view of the varied response regarding its effectiveness from various multicenter studies, there is a need to conduct more single center population-specific studies. We, thus, aimed to assess the role of convalescent plasma therapy in COVID-19 patient management in a single -center. This retrospective study was conducted using records of all COVID-19 patients who received plasma therapy over a period of 6 months in a dedicated COVID-19 hospital in Delhi. Information pertaining to transfusion, disease severity, associated comorbidities, the treatment given and patient outcome were recorded. Data was analyzed using SPSSv23. Of the141 patients who received plasma therapy, 62% were discharged after treatment. Mortality was found to be significantly higher in patients > 60 years of age (p < 0.001), those with severe COVID-19 infection (p < 0.05) and pre-existing renal disease (p < 0.05). The admission-transfusion interval was significantly correlated to mortality and was a sensitive parameter for predicting outcome at cut off value of < 5 days (p < 0.001). There was no significant association of mortality with patient blood group, plasma antibody levels or donor hemoglobin levels. We report improvement and recovery in a large number of patients who received convalescent plasma within the first 5 days of hospitalization with moderate to severe disease. Further research to compare dosage and administration protocols to delineate role of CCP in survival of COVID-19 patients is needed before it is prematurely shelved.
Identifiants
pubmed: 35618641
pii: S1473-0502(22)00128-8
doi: 10.1016/j.transci.2022.103455
pmc: PMC9090870
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103455Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Références
Ann Intensive Care. 2021 May 12;11(1):73
pubmed: 33978844
J Exp Med. 1913 May 1;17(5):553-76
pubmed: 19867668
J Infect. 2017 Mar;74(3):302-309
pubmed: 27867062
Ear Nose Throat J. 2021 Apr;100(2_suppl):140S-147S
pubmed: 33155834
PLoS One. 2021 Jul 28;16(7):e0254453
pubmed: 34320004
Blood Cells Mol Dis. 2021 May;88:102548
pubmed: 33621948
Mayo Clin Proc. 2021 May;96(5):1262-1275
pubmed: 33958057
PLoS One. 2020 Nov 18;15(11):e0241541
pubmed: 33206661
J Transl Int Med. 2021 Jul 09;9(2):68-70
pubmed: 34497745
J Clin Med. 2021 May 10;10(9):
pubmed: 34068725
Br J Haematol. 2020 Jul;190(1):e27-e29
pubmed: 32407543
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Clin Microbiol Newsl. 2021 Feb 15;43(4):23-32
pubmed: 33564204
Ann Med. 2021 Dec;53(1):227-236
pubmed: 33345626
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Lancet. 1979 Dec 8;2(8154):1216-7
pubmed: 92624
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Transfusion. 2020 Jun;60(6):1332-1333
pubmed: 32374890
Ann Intern Med. 2006 Oct 17;145(8):599-609
pubmed: 16940336
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Ann Hematol. 2020 Sep;99(9):2113-2118
pubmed: 32656591
Transfus Apher Sci. 2020 Jun;59(3):102794
pubmed: 32448638
Pharmacol Res Perspect. 2021 Feb;9(1):e00691
pubmed: 33378565